STONY BROOK, NY — August 14, 2025 — Leads & Copy — Applied DNA Sciences, Inc. (NASDAQ:APDN) reported its financial results for the third quarter of fiscal 2025, which ended June 30, 2025. The company’s Form 10-Q is available on the SEC Filings page of its Investor Relations website.
Following a recent restructuring, Applied DNA, via its LineaRx, Inc. subsidiary, is now focused on synthetic DNA and mRNA manufacturing solutions for biotherapeutics, such as gene therapies, personalized medicine, and DNA vaccines. The company is commercializing LineaDNA™, LineaRNAP™, and LineaIVT™ technologies for DNA production.
Judy Murrah, chairperson, president, and CEO of Applied DNA, stated that operational activities are centering on repositioning Applied DNA as a single business aligned with its core competencies. The company is focused on delivering value to shareholders.
Key Financial Results:
Total revenues: $304 thousand.
Operating loss: $3.7 million.
Adjusted EBITDA: Negative $3.9 million.
Cash and cash equivalents as of June 30, 2025: $4.7 million.
The company also announced the launch of the LineaRx IVT Discovery Kit and industry marketing for LineaRNAP as a standalone product. Applied DNA initiated ISO 13485 certification to enhance customer trust and expand market opportunities.
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Source: Applied DNA Sciences
